HONG KONG (MarketWatch)-- Hong Kong stocks rose early Thursday, as China Mobile Ltd. shined on news of iPhone pre-orders hitting 1 million units. The Hang Seng Index (HK:HSI) added 0.6% to 23,032.09. Market heavyweight China Mobile (HK:941) (CHL) rallied 0.9%, as the world's largest mobile carrier said it has received more than 1 million pre-orders for the iPhone before it goes on sale in the carrier's stores on Friday, at a time when Apple Inc. (AAPL) Chief Executive Tim Cook visited Beijing for future cooperation between the two giants. Telecom equipment shares also advanced, with ZTE Corp. (HK:763) (ZTCOF) rising 1.2%. Meanwhile, China Mobile's smaller rivals slipped, as China Unicom (HK:762) (CHU) dropped 0.7%, and China Telecom (HK:738) (CNCT) fell 0.5%. China South City Holdings (HK:1668) , a developer of logistics and trade centers, surged 56%, after the company announced that Internet giant Tencent Holdings (HK:700) (TCTZF) would invest about 1.5 billion Hong Kong dollars ($195 million) for an almost 10% stake in the developer in order to expand their business online, including e-commerce and online payment services. Tencent Holdings (HK:700) (TCTZF) climbed 3%. On the mainland, the Shanghai Composite (CN:SHCOMP) edged down 0.1% at 2,021.62.
Best Recreation Stocks To Buy For 2015: Public Service Enterprise Group Incorporated(PEG)
Public Service Enterprise Group Incorporated, through its subsidiaries, operates in the energy industry primarily in the northeastern and mid Atlantic United States. The company primarily operates as a wholesale energy supply company that integrates its generating asset operations through its wholesale energy, fuel supply, energy trading, and marketing and risk management activities. It operates nuclear, coal, gas, and oil-fired generation facilities. The company also involves in the transmission of electricity and distribution of electricity and natural gas to residential, commercial, and industrial customers, as well as invests in the development of solar generation projects and energy efficiency programs. In addition, it owns and operates domestic projects engaged in the generation of energy; and offers appliance services and repairs to customers. As of December 31, 2010, it owned approximately 13,538 megawatts of generation capacity. The company also owned and operated approximately 17,608 miles of gas mains, 12 gas distribution headquarters, and 2 subheadquarters, as well as 62 natural gas metering and regulating stations. Public Service Enterprise Group was founded in 1985 and is based in Newark, New Jersey.
Advisors' Opinion:- [By Shauna O'Brien]
Jefferies announced on Tuesday that it has upgraded Public Service Enterprise Group Inc. (PEG).
The firm has lifted its rating on PEG from “Hold” to “Buy,” and has raised the company’s price target from $36 to $37. This price target suggests a 12% increase from the stock’s current price of $32.42.
Analyst Paul Fremont commented: “We are upgrading to Buy based on the improving outlook for regulatory approval of the company’s “Energy Strong” capital spending program.
“Each $1.0 billion of incremental spending will add an estimated $0.10 to PEG’s earnings. We assume that incremental spending is funded by debt and by incremental cash expected from the increasing gas basis differential between the Leidy hub and New Jersey. Our new estimates are considerably higher than consensus in 2014-16.”
Public Service Enterprise Group shares were mostly flat during pre-market trading Tuesday. The stock is up 6% YTD.
- [By Monica Wolfe]
According to the Dividend Channel, Public Service Enterprise (PEG) has been named as the ��op Dividend Stock of the Dow Utilities��as of its most recent DividendRank report. The report states that Public Service Enterprise has demonstrated ��ttractive valuation metrics��as well as ��trong profitability metrics.��
Top 5 Logistics Companies To Watch For 2014: Investview Inc (INVU)
InvestView, Inc. (InvestView), incorporated on April 20, 2005, is an investor technology and education company. The Company provides a broad suite of products that allow the individual investor to find, analyze, track and manage his or her portfolio. The Company's educational services focus on empowering investors with the skills that allow them to rely on their own investing knowledge to make intelligent and sound investment decisions. The Company's flagship product is InvestView, an on-line education, analysis and application platform. InvestView is equipped with in-house, qualified professionals who have collectively taught over a quarter of a million students in the past decade on how to trade in the stock market. The Company specializes in assisting common investors through this process by offering them the tools, training and confidence that is required to successfully navigate the market in these trying times.
The Company helps the everyday investor turn market uncertainty into opportunity. The Company does this by providing investment tools and training , coupled with a rules-based system that allows individuals to makes more intelligent and disciplined investment decisions. The Company�� offerings include a comprehensive program of successively more complex financial educational courses that are sold to customers on a subscription basis and are delivered on line through the Company�� Website; Inhouse developed trading tools with actionable trading indicators; Blogs, newsletters and other reference materials that describe investment strategies, and Mentoring, coaching and advisory services that are available on a subscription basis.
The principal tool the Company offers is Market Point. It consists of five categories for both fundamental and technical analysis for proper stock evaluation: Charts, Stock Watch, Markets, Calendars and Campus.
The Company's 7-Minute Trader is the first of the 7-Minute products. The 7-Minute Trader was developed for everyone who ! is frustrated with the returns inside of their retirement accounts and personal investment portfolios, but just do not have the time to do all of the necessary research themselves. The Company created a program that literally takes just seven minutes per week. The Company accomplishes this through a newsletter that is sent out every week with just a single trade idea in it.
The Company�� 7-Minute Stocks product was introduced to address those subscribers who have expressed an interest in adding an equity strategy. Similar to the 7-Minute Trader, the 7-Minute Stocks product is scalable since it provides only on-demand education and one new trade idea per week via its newsletter service. Contrary to the 7-Miinute Trader, the 7-Minute Stocks is a more conservative, longer time horizon product. Most 7-Minute Stocks trades are expected to be held for multiple weeks or even months in duration compared to just 2-3 days for the 7-Minute Trader.
The Company�� 7-Minute Options product was introduced to address those subscribers who wanted a less aggressive option trading strategy than the one provided with the 7-Minute Trader. Similar to the 7-Minute Trader, the 7-Minute Options product is scalable since it provides only on-demand education and one new trade idea per week via its newsletter service. Contrary to the 7-Minute Trader, the 7-Minute Options is a more conservative, slightly longer time horizon product. Most 7-Minute Options trades are expected to be held for 2-8 weeks in duration compared to 2-3 days for the 7-Minute Trader.
The Company competes with Edgar Online, BankRate.com, TheStreet.com and Morningstar.
Advisors' Opinion:- [By Jonathan Yates]
Options expert Dr. Joseph Louro, head of Investview (OTC: INVU), an investor education and financial technology entity, says that more than 70 percent of options are never exercised. And that makes selling covered call options on a company like BHP Billiton even more rewarding and even less risky.
- [By Jonathan Yates]
Louro, who is the head of Investview (OTC: INVU), emphasizes this as the overall appeal of this strategy. Many buyers of options do it for hedging purposes.
Top 5 Logistics Companies To Watch For 2014: Bridgepoint Education Inc (BPI)
Bridgepoint Education, Inc. (Bridgepoint), incorporated in May 1999, is a provider of postsecondary education services. The Company�� academic institutions include Ashford University and University of the Rockies. Its institutions deliver programs primarily online, as well as at their traditional campuses. As of December 31, 2011, the Company had 86,642 total students enrolled in its institutions. Bridgepoint�� institutions conduct ongoing faculty and student assessment processes and provide a range of student services. The Company is also focused on developing new technologies, such as through Waypoint Outcomes, Constellation, and the development of its institutions' mobile learning platforms. The Company has developed Constellation to replace third party textbooks with digital course materials. Constellation materials are displayed in a browser-based platform. In January 2012, Bridgepoint introduced Thuze.
Ashford University offers associate's, bachelor's and master's degree programs online, as well as bachelor's degree programs at its campus in Clinton, Iowa. Ashford University consists of four colleges: the College of Business and Professional Studies, the College of Education, the College of Health, Human Services and Sciences, and the College of Liberal Arts. University of the Rockies is a graduate institution that offers master's and doctoral degree programs in the social and behavioral sciences. Classes at University of the Rockies are presented in a progressive online format, as well as at its campus in Colorado Springs, Colorado. Waypoint Outcomes provides learning and assessment software to K-12 and higher education institutions nationwide.
Constellation provides mobile access to students over the Internet, as well as on a variety of devices, including Web-enabled smartphones and tablet devices. Constellation is a cloud-based and is compatible across operating systems, browsers and mobile technologies. The Company has developed Constellation-enabled courses pri! marily in core classes to reach students. As of December 31, 2011, approximately 76% of Bridgepoint�� institutions' students had taken a Constellation-enabled course. As of December 31, 2011, it had 32 Constellation titles available. Thuze is a cloud-based, multi-platform, collaborative learning environment for students to interact with their course digital materials and with each other. Thuze provides students with the resources to work from both their desktop computers and also from their tablets and smartphones. It launched Thuze as a pilot program with publishers in higher education. During the year ended December 31, 2011, the Company deployed new mobile application technology at Ashford University. The Company has online students from all 50 states and from the District of Columbia. It has students from 69 different countries. As of December 31, 2011, over 34,400 students have graduated from the Company�� institutions, with approximately 15,200 students graduating from its institutions, during 2011.
Students finance their education at the Company's institutions through Title IV programs and Non-Title IV funding sources. Title IV programs includes The Federal Family Education Loan (FFEL) and Federal Direct Loan Programs. FFEL and Federal Direct Loan Programs consist of two loans: Stafford loans, which are either subsidized or unsubsidized, and PLUS loans, which are made available to graduate and professional students, as well as parents of dependent undergraduate students. Non-Title IV funding sources include other funding sources, which consist of cash, private loans, state grants, corporate reimbursement, military benefits and institutional loans. The Company has engaged Affiliated Computer Services, Inc. (ACS) to provide call center and transactional processing services for the online financial aid student populations at its institutions, including services related to disbursement eligibility review and Title IV fund returns. If Bridgepoint�� engagement with ACS were terminate! d, it wou! ld handle these processing services using its own resources or engage another third party vendor.
The Company�� institutions provide student support services, including academic, administrative and technology support. As of December 31, 2011, Bridgepoint�� institutions offered approximately 1,430 courses, 85 degree programs and 140 specializations. Its institutions offer programs and specialization areas through Ashford University's four colleges: the College of Business and Professional Studies; the College of Education; the College of Health, Human Services and Science; and the College of Liberal Arts, and through the University of the Rockies' two schools: the School of Organizational Leadership and the School of Professional Psychology. The Company�� leads are primarily generated from online sources. Its main source of leads is third party online lead aggregators. It also purchases keywords from search providers to generate online leads directly. In addition, the Company has an in-house team focused on generating online leads.
Advisors' Opinion:- [By Jim Royal]
One of my favorite reasons to reinvest in stocks I already own is when an uncertain, but favorable catalyst occurs, but the stock does little. So my Special Situations portfolio is adding $1,000 to each of the following three stocks: Cincinnati Bell (NYSE: CBB ) , Bridgepoint Education (NYSE: BPI ) , and First Financial Northwest (NASDAQ: FFNW ) . Read on to see why.
- [By Jake L'Ecuyer]
Bridgepoint Education (NYSE: BPI) shares tumbled 11.37 percent to $14.11 after the company announced a Q1 preliminary loss of $0.10 per share on sales of $160.5 million. The company also reported that it will be unable to file 10Q by May 12th.
Top 5 Logistics Companies To Watch For 2014: Galena Biopharma Inc (GALE)
Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). On January 19, 2012, the Company initiated enrollment in its Phase 3 PRESENT clinical trial for NeuVax (E75 peptide plus GM-CSF) vaccine in low-to-intermediate HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment study is a randomized, multicenter, multinational clinical trial that will enroll approximately 700 breast cancer patients. The Company�� Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival (DFS). On April 13, 2011, the Company completed its acquisition of Apthera, Inc.,(Apthera).
The Company focuses to start a Phase 2 trial comparing NeuVax in combination with trastuzumab (Herceptin) versus trastuzumab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting. The Company's second product candidate, Folate Binding Protein-E39 (FBP), is a vaccine, consisting of the peptides E39 and J65, aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. On February 14, 2012, the Company announced the initiation of a Phase 1/2 clinical trial in two gynecological cancers: ovarian and endometrial adenocarcinomas. Folate binding protein has ! very limited tissue distribution and expression in non-malignant tissue and is over-expressed in more than 90% of ovarian and endometrial cancers, as well as in 20% to 50% of breast, lung, colorectal and renal cell carcinomas.
In April 2011, the Company acquired Apthera Inc and its NeuVax product candidate. The Company focuses on developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide, the advanced of which is NeuVax, which is targeted at preventing the recurrence of breast cancer. NeuVax has had positive Phase 1/2 clinical trial results for the prevention of breast cancer recurrence in patients who have had breast cancer and received the standard of care treatment (surgery, chemotherapy, radiotherapy and hormonal therapy as indicated). The Company had also initiated its Phase 3 PRESENT clinical trial of NeuVax for the prevention of breast cancer recurrence in early-stage low-to-intermediate HER2 breast cancer patients. NeuVax directs killer T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. NeuVax is comprised of a HER2/neu-derived peptide called E75. E75 is a nine-amino acid sequence that is immunogenic (produces an immune response) and GM-CSF is a commercially available protein that acts to stimulate and activate components of the immune system such as macrophages and dendritic cells.
The Company also develops novel applications for NeuVax based on preclinical studies and phases 2 clinical trials which suggest that combining NeuVax and trastuzumab (Herceptin; Genentech/Roche) can increase antigen presentation by tumor cells by promoting receptor internalization and subsequent proteosomal degradation of the HER2 protein. The Company also is pursuing additional therapeutic indications for NeuVax that are in Phase 1/2 clinical trials. RXI-109, is a dermal anti-scarring therapy that targets! connecti! ve tissue growth factor (CTGF) and that may inhibit connective tissue formation in human fibrotic disease.
The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc., GlaxoSmithKline plc, Renovo Group plc, CoDa Therapeutics, Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene, Derma Sciences, Inc., Healthpoint Biotherapeutics, Pharmaxon, Excaliard Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris.
Advisors' Opinion:- [By Paul Ausick]
Stocks on the move: Galena Biopharma Inc. (NASDAQ: GALE) is down 15.4% at $1.93 after pricing a secondary offering of 17.5 million units at $2.00. Safeway Inc. (NYSE: SWY) is up 6.1% at $28.21, after an analyst�� upgrade which sent shares to a new 52-week high of $28.88 earlier. Avanir Pharmaceuticals Inc. (NASDAQ: AVNR) is down 18.2% at $4.08.
No comments:
Post a Comment